SEC Filing Intelligence
Biotech BD & Licensing Events
Classified 8-K events from SEC EDGAR: licensing agreements, strategic alternatives, M&A signals, and financing activity. Tagged by deal type and linked to company identifiers. Updated 3× daily from primary filings.
Request dataset →Live Sample
What the data looks like
Live data from our pipeline.
BioCryst Pharmaceuticals has entered into an exclusive license agreement with an Irish affiliate of Neopharmed Gentili S.p.A. for the commercialization of navenibart in Europe for hereditary angioedema. BioCryst will receive an upfront payment of $70 million, with potential for up to $275 million in future regulatory and sales milestone payments. Additionally, BioCryst will earn tiered royalties on net sales ranging from 18% to 30%.
Atara Biotherapeutics, Inc. announced a regulatory update regarding its drug EBVALLO™. The company held a Type A meeting with the FDA to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the EBVALLO™ Biologics License Application.
Werewolf Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1 to this Form 8-K. The company specified that this financial information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
BridgeBio Pharma, Inc. entered into a new "at-the-market" (ATM) equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, allowing the company to sell up to $500 million of its common stock. This agreement, effective May 7, 2026, replaces a previous ATM agreement from May 2023. The company is not obligated to sell any shares, and the sales agents will receive a commission of up to 3.0% on gross proceeds.
MacroGenics, Inc. amended its royalty purchase agreement with Sagard Healthcare Partners regarding global net sales of ZYNYZ (retifanlimab-dlwr). The company received an additional $60 million cash payment, bringing the total purchase price from Sagard to $130 million for the royalty rights. The amendment also revises Sagard's capped royalty interest and introduces a potential $20 million sales-based milestone payment for MacroGenics.
Live data from our pipeline. The structured export includes all fields listed below.
Use Cases
Who Uses This Data
Structured for direct analysis. No data cleaning, no manual joins required.
Healthcare Investment Banking
- ● Track licensing deal flow across therapeutic areas for pitch book and comp research
- ● Monitor strategic alternative announcements as M&A lead indicators
- ● Identify financing events and proceeds amounts for comparable transaction analysis
- ● Export structured deal data to populate precedent transaction databases
Corporate Business Development
- ● Monitor competitor licensing activity in your therapeutic area as it files
- ● Track strategic review announcements as potential partnership or acquisition signals
- ● Stay current on financing events that indicate pipeline funding status
- ● Cross-reference deal signals with clinical trial milestones for full pipeline context
What's Included
Data Fields
Primary Sources
- • SEC EDGAR 8-K filings (primary source)
- • 500+ tracked public biotech companies
- • Auto-classification by deal type and signal category
Fields Include
- • Company name, ticker, and SEC CIK
- • Filing date and 8-K accession number
- • Signal type (Licensing, Strategic Review, M&A, Financing, FDA Action, Clinical Data)
- • Deal excerpt auto-extracted from filing text
- • Counterparty name (where detectable)
- • Proceeds amount (financing events)
- • Link to original SEC EDGAR document
- • Linked trial count and phase distribution per company
Get the Data
Got it.
We'll follow up shortly.